A Phase I, Double-Blind, Randomized, Multiple-Dose, Pilot Study Comparing Xanomeline Administered Alone to Xanomeline Administered in Combination With Trospium Chloride in Normal Healthy Volunteers

This study is intended to determine whether the addition of trospium chloride to xanomeline tartrate will ameliorate the peripheral cholinergic side effects that have been previously experienced with xanomeline tartrate when administered alone.

开始日期2016-09-07

申办/合作机构

Karuna Therapeutics, Inc.

100 项与 Xanomeline 相关的临床结果

登录后查看更多信息

100 项与 Xanomeline 相关的转化医学

登录后查看更多信息

100 项与 Xanomeline 相关的专利（医药）

登录后查看更多信息

172

项与 Xanomeline 相关的文献（医药）

2024-01-01·Lancet (London, England)1区 · 医学

Efficacy and safety of the muscarinic receptor agonist KarXT (xanomeline–trospium) in schizophrenia (EMERGENT-2) in the USA: results from a randomised, double-blind, placebo-controlled, flexible-dose phase 3 trial

1区 · 医学

Article

作者: Correll, Christoph U ; Paul, Steven M ; Zhu, Haiyuan ; Sawchak, Sharon ; Kaul, Inder ; Miller, Andrew C ; Brannan, Stephen K ; Kakar, Rishi ; Breier, Alan

BACKGROUND:

New treatments with new mechanisms are urgently needed for people with schizophrenia. Xanomeline is a dual M₁ and M₄-preferring muscarinic receptor agonist that does not block D₂ dopamine receptors, unlike all currently approved treatments for schizophrenia. Xanomeline-trospium (KarXT) combines xanomeline with the peripherally restricted muscarinic receptor antagonist trospium chloride with the goal of ameliorating xanomeline-related adverse events associated with peripheral muscarinic receptors. The EMERGENT-2 trial aimed to assess the efficacy and safety of KarXT in people with schizophrenia experiencing acute psychosis.

METHODS:

EMERGENT-2 was a randomised, double-blind, placebo-controlled, flexible-dose, 5-week, inpatient, phase 3 trial in people with schizophrenia. Participants were adults aged 18-65 years with a diagnosis of schizophrenia who had a recent worsening of psychosis warranting hospital admission, a Positive and Negative Syndrome Scale (PANSS) score of 80 or higher, and a Clinical Global Impression-Severity score of 4 or higher. The participants were recruited from 22 inpatient sites in the USA, and were randomly assigned (1:1) to KarXT or placebo twice per day. Participants randomly assigned to KarXT received 50 mg xanomeline and 20 mg trospium twice per day for the first 2 days and then 100 mg xanomeline and 20 mg trospium twice per day for days 3-7. Beginning on day 8, KarXT dosing was flexible with an optional increase to 125 mg xanomeline and 30 mg trospium twice per day and the option to return to 100 mg xanomeline and 20 mg trospium based on tolerability. The primary endpoint was change from baseline to week 5 in PANSS total score. Efficacy analyses used the modified intention-to-treat population (all randomly assigned participants who received at least one trial medication dose and had at least one post-baseline PANSS assessment). Least squares mean change from baseline, SE, and least squares mean difference between the KarXT and placebo groups at week 5, along with the 95% CI and two-sided p values were calculated for the primary and secondary continuous efficacy endpoints. Safety analyses included all participants receiving at least one trial medication dose and used descriptive statistics. This trial is registered with ClinicalTrials.gov (NCT04659161).

FINDINGS:

From Dec 16, 2020, to April 13, 2022, of 407 people who were screened, 252 participants meeting enrolment criteria were randomly assigned to the KarXT (n=126) or placebo (n=126). Baseline PANSS total scores were 98·3 (KarXT; n=126) and 97·9 (placebo; n=125). The trial met the primary endpoint with a mean change from baseline to week 5 in PANSS total score that favoured KarXT (-21·2 points, SE 1·7) versus placebo (-11·6 points, 1·6; least squares mean difference -9·6; 95% CI -13·9 to -5·2; p<0·0001, Cohen's d effect size=0·61). All secondary endpoints were also met, and favoured KarXT versus placebo (p<0·05). The most common adverse events with KarXT versus placebo were constipation (27 [21%] vs 13 [10%]), dyspepsia (24 [19%] vs 10 [8%]), headache (17 [14%] vs 15 [12%]), nausea (24 [19%] vs seven [6%]), vomiting (18 [14%] vs one [1%]), hypertension (12 [10%] vs one [1%]), dizziness (11 [9%] vs four [3%]), gastro-oesophageal reflux disease (eight [6%] vs zero [0%]), and diarrhoea (seven [6%] vs four [3%]). Treatment-emergent adverse event rates of extrapyramidal motor symptoms (KarXT, zero [0%] vs placebo, zero [0%]), akathisia (one [1%] vs one [1%]), weight gain (zero [0%] vs one [1%]), and somnolence (six [5%] vs five [4%]) were similar between the KarXT and placebo groups, as were adverse event-related discontinuation rates (nine [7%] vs seven [6%]).

INTERPRETATION:

In the EMERGENT-2 trial, KarXT was effective in reducing positive and negative symptoms and was generally well tolerated. These results support the potential for KarXT to represent a new class of effective and well tolerated antipsychotic medicines based on activating muscarinic receptors, not the D₂ dopamine receptor-blocking mechanism of all current antipsychotic medications. Results from additional trials, including the identical EMERGENT-3 trial and the 52-week, open-label EMERGENT-4 and EMERGENT-5 trials, will provide additional information on the efficacy and safety of KarXT in people with schizophrenia.

FUNDING:

Karuna Therapeutics.

2023-12-02·Expert Opinion on Investigational Drugs

Muscarinic M1 and M4 receptor agonists for schizophrenia: promising candidates for the therapeutic arsenal

Review

作者: Dean, Brian

INTRODUCTION:

Successful phase 3 trials of KarXT in people with schizophrenia herald a new era of treating the disorder with drugs that do not target the dopamine D2 receptor. The active component of KarXT is xanomeline, a muscarinic (CHRM) M1 and M4 agonist, making muscarinic receptors a viable target for treating schizophrenia.

AREAS COVERED:

This review covers the process of taking drugs that activate the muscarinic M1 and M4 receptors from conceptualization to the clinic and details the mechanisms by which activating the CHRM1 and 4 can affect the broad spectrum of symptoms experienced by people with schizophrenia.

EXPERT OPINION:

Schizophrenia is a syndrome which means drugs that activate muscarinic M1 and M4 receptors, as was the case for antipsychotic drugs acting on the dopamine D2 receptor, will not give optimal outcomes in everyone within the syndrome. Thus, it would be ideal to identify people who are responsive to drugs activating the CHRM1 and 4. Given knowledge of the actions of these receptors, it is possible treatment non-response could be restricted to sub-groups within the syndrome who have deficits in cortical CHRM1 or those with one of the cognitive endophenotypes that may be identifiable by changes in the blood transcriptome.

M1 Cholinergic Signaling Modulates Cytokine Levels and Splenocyte Sub-Phenotypes Following Cecal Ligation and Puncture

作者: Brewer, Mariana R ; Abraham, Mabel N ; Deutschman, Clifford ; Fernandes, Tiago ; Taylor, Matthew D ; Nedeljkovic-Kurepa, Ana ; Yaipen, Omar

Abstract:

Background: The contribution of the central nervous system to sepsis pathobiology is incompletely understood. In previous studies, administration of endotoxin to mice decreased activity of the vagus anti-inflammatory reflex. Treatment with the centrally-acting M1/M4 muscarinic acetylcholine (ACh) receptor (M1/M4AChR) attenuated this endotoxin-mediated change. We hypothesize that decreased M1/M4AChR-mediated activity contributes to inflammation following cecal ligation and puncture (CLP), a mouse model of sepsis. Methods: Basal forebrain cholinergic activity (immunostaining), serum cytokine/chemokine levels (ELISA) and splenocyte subtypes (flow cytometry) were examined at baseline and following CLP in male C57BL/6 male mice. Rersults: At 48hrs. post-CLP, activity in basal forebrain cells expressing choline acetyltransferase (ChAT) was half of that observed at baseline. Lower activity was also noted in the hippocampus, which contains projections from ChAT-expressing basal forebrain neurons. Serum levels of TNFα, IL-1β, MIP-1α, IL-6, KC and G-CSF were higher post-CLP than at baseline. Post-CLP numbers of splenic macrophages and inflammatory monocytes, TNFa+ and ILb+ neutrophils and ILb+ monocytes were higher than baseline while numbers of central Dendritic Cells (cDCs), CD4+ and CD8+ T cells were lower. When, following CLP, mice were treated with xanomeline, a central-acting M1AChR agonist, activity in basal forebrain ChAT-expressing neurons and in the hippocampus was significantly higher than in untreated animals. Post-CLP serum concentrations of TNFα, IL-1β, and MIP-1α, but not of IL-6, KC and G-CSF, were significantly lower in xanomline-treated mice than in untreated mice. Post-CLP numbers of splenic neutrophils, macrophages, inflammatory monocytes and TNFα+ neutrophils also were lower in xanomeline-treated mice than in untreated animals. The effects of CLP on percentages of IL-1β+ neutrophils, IL-1β+ monocytes, cDCs, CD4+ T cells and CD8+ T cells were similar in xanomeline - treated and untreated post-CLP mice. Conclusion: Our findings indicate thatM1/M4AChR-mediated responses modulate CLP-induced alterations in the distribution of some, but not all, leukocyte phenotypes and certain cytokines and chemokines.

项与 Xanomeline 相关的新闻（医药）

2024-04-10

·Firstwordpharma

PureTech seeks a CNS success repeat in Seaport

Fresh off the success of schizophrenia-focused Karuna Therapeutics, which Bristol Myers Squibb recently acquired for $14 billion, PureTech Health made another neurology bet on Tuesday, launching Seaport Therapeutics with a $100-million oversubscribed series A. “You can sort of see echoes of Karuna with the story of Seaport Therapeutics,” Michael Chen, one of biotech’s co-founders, told FirstWord. Both were founded by PureTech to address a massive unmet need in central nervous system (CNS) disorders, and some of the investors in Seaport’s A round – including co-lead investors ARCH Venture Partners and Sofinnova Investments – were early backers of Karuna. Plus, key members of Karuna’s leadership team have returned to helm Seaport. CEO Daphne Zohar helped found both PureTech and Karuna, and board chair Steven Paul previously served as CEO and chair of Karuna prior to its buyout. The two companies also were created with a similar goal, according to Chen. Take a compound with known efficacy – and known drawbacks – and solve the existing problems “to get the optimal profile for patients.” For Karuna, it was about fixing the tolerability issues with xanomeline, which had previously demonstrated antipsychotic benefits in a schizophrenia study run by Eli Lilly, but ultimately was dropped due to a high rate of gastrointestinal side effects. The result of Karuna’s efforts, KarXT (xanomeline-trospium), recently posted positive long-term safety and efficacy data and is awaiting an FDA decision in September. From the outset, Seaport’s mission is a bit broader: to use its Glyph platform to improve known mood disorder treatments in varied ways, such as creating an oral version or avoiding liver toxicities.Going the lymphatic routeSeaport holds an exclusive licence to the Glyph platform from the lab of Chris Porter at Monash University. The technology exploits the lymphatic system to allow bypassing of the liver. By attaching a fat molecule, a therapeutic compound is treated as a dietary fat and absorbed directly into the bloodstream, avoiding first-pass metabolism. To Chen’s knowledge, no other group is pursuing drug delivery using the lymphatic system, which he called a “dark area of biology.”“No one really ever talks about how olive oil is absorbed,” he explained. “But in this case, we’re able to use this proprietary chemistry platform to take advantage of the way the body absorbs things like olive oil and actually solve a really important problem, which is that a lot of these CNS drugs are effective or potent or active and have, in some cases, clinical data showing that they work, but they are held back by some key flaw or deficit.” Seaport’s lead candidate, SPT-300, is a prodrug of allopregnanolone in Phase II testing. The neurosteroid has been shown to be effective for postpartum depression, but required a 60-hour IV infusion, Chen said. SPT-300 is given as a pill and has already demonstrated proof-of-concept in a clinical model of anxiety in healthy volunteers.The biotech’s preclinical pipeline includes SPT-320, a prodrug of agomelatine for generalised anxiety disorder, and SPT-348, a prodrug of non-hallucinogenic neuroplastogen for mood and other neuropsychiatric disorders.Agomelatine is approved in Europe and Australia for anxiety, Chen said, but because much of the drug is broken down in the liver before it reaches the bloodstream, it can cause transient adaptive increases in liver enzymes. Patients on the drug are required to undergo frequent liver function tests to monitor the liver side effects.

临床2期并购上市批准引进/卖出

2024-04-09

·药明康德

潜在首款！百时美施贵宝创新机制疗法长期试验结果积极

近日，百时美施贵宝（Bristol Myers Squibb）公司公布了其潜在“first-in-class”疗法KarXT（xanomeline-trospium）用于治疗成人精神分裂症患者的3期临床试验EMERGENT-4的最新中期数据。结果显示，接受KarXT治疗52周，精神分裂症患者的症状在所有疗效指标上均有显著改善。此前，KarXT用于治疗成人精神分裂症的新药申请（NDA）已被美国FDA受理，PDUFA目标日期为2024年9月26日。根据新闻稿，如果获得批准，KarXT将成为数十年来用于治疗精神分裂症的首个新机制药物。 EMERGENT-4是一项为期52周的3期开放标签扩展研究，旨在评估KarXT在成人精神分裂症患者中的长期安全性、耐受性和疗效，这些患者之前已完成了为期5周的双盲、安慰剂对照的疗效和安全性3期试验EMERGENT-2或EMERGENT-3的其中一项。截至2023年4月17日的数据，共有110名患者参与了中期疗效分析，其中29名患者已完成52周的治疗。中期分析显示，52周时，KarXT能显著改善精神分裂症患者所有症状的疗效指标。根据阳性和阴性综合征量表（PANSS）评分，在开放标签延长期结束时，超过75%的患者症状改善超过30%，与基线（98.4分）相比平均减少33.3分。此外，受试者的临床整体印象-严重程度（CGI-S）评分与基线（5.2分）相比平均改善了1.7分，从基线时的"明显不适"转变为一年后的"中度不适"或"轻度不适"。在为期52周的试验中，无论受试者之前在急性试验期间接受的是KarXT还是安慰剂治疗，其精神分裂症症状的改善都在持续。在参加开放标签扩展试验之前，曾在EMERGENT-2和EMERGENT-3试验中接受过安慰剂治疗患者的PANSS平均评分显著高于接受KarXT治疗的患者（86.5分对比76.1分）。之前接受安慰剂的患者在接受KarXT治疗后的两周内症状获明显改善。四周后，在急性试验中接受KarXT或安慰剂治疗患者的PANSS评分相当。此外，KarXT对患者的体重和长期代谢状况也产生了有利影响，大多数患者在52周的治疗过程中，代谢指标趋于稳定或有所改善。在长期试验中，KarXT的耐受性普遍良好，其副作用与之前针对精神分裂症患者进行的KarXT试验一致。在52周的治疗过程中，KarXT不会导致泌乳素发生显著变化，也不会导致运动障碍量表评分发生有临床意义的变化。 KarXT是Karuna Therapeutics开发的一款口服M1/M4型毒蕈碱乙酰胆碱受体激动剂，正在开发用于治疗精神和神经系统疾病，包括精神分裂症和痴呆相关精神病性障碍，具有潜力成为首款非靶向多巴胺能与5-羟色胺能信号通路，并具双重机制的新式药物。2023年12月，百时美施贵宝以约140亿美元的总额收购了Karuna公司，并获得了KarXT。再鼎公司拥有这款创新疗法在大中华区的研发权益，KarXT在2022年已经在中国获批临床。 KarXT由xanomeline和trospium chloride两种有效成分构成，旨在激活大脑中的毒蕈碱型乙酰胆碱受体的同时，减少对外周毒蕈碱型乙酰胆碱受体的作用。通过刺激毒蕈碱受体M1和M4受体，xanomeline可缓解负面症状，如冷漠、社会驱动力减少、提高认知能力，并对改善其它精神症状，如幻觉和妄想很有帮助。而季铵盐化合物trospium chloride为毒蕈碱受体拮抗剂，可抑制xanomeline于外周神经中的副作用。参考资料：[1] Bristol Myers Squibb Presents New Interim Long-Term Efficacy Data from the EMERGENT-4 Trial Evaluating KarXT in Schizophrenia at the 2024 Annual Congress of the Schizophrenia International Research Society. Retrieved April 8, 2024, from https://news.bms.com/news/corporate-financial/2024/Bristol-Myers-Squibb-Presents-New-Interim-Long-Term-Efficacy-Data-from-the-EMERGENT-4-Trial-Evaluating-KarXT-in-Schizophrenia-at-the-2024-Annual-Congress-of-the-Schizophrenia-International-Research-Society/default.aspx 内容来源于网络，如有侵权，请联系删除。

临床结果

2024-04-09

·BioSpace

Seaport Therapeutics Launches with $100 Million Oversubscribed Series A Financing Round to Advance Novel Neuropsychiatric Medicines

Daphne Zohar, Founding CEO of PureTech Health and Co-Founder of Karuna Therapeutics, is Founder, Chief Executive Officer and Member of the Board of Directors of Seaport Steven M. Paul, M.D., former CEO and Chair of Karuna Therapeutics, President of Lilly Research Laboratories, is Founder and Chair of the Board of Directors of Seaport BOSTON--(BUSINESS WIRE)-- Seaport Therapeutics, a clinical-stage biopharmaceutical company that is charting a proven path in neuropsychiatry, today announced the closing of a $100 million oversubscribed Series A financing round. The round was co-led by ARCH Venture Partners and Sofinnova Investments along with Third Rock Ventures and Seaport founder PureTech Health. Seaport also announced the appointment of Daphne Zohar as Founder, Chief Executive Officer and a member of the Board of Directors, and Steven M. Paul, M.D., as Founder and Chair of the Board of Directors. Seaport is advancing a clinical-stage pipeline of novel neuropsychiatric medicines powered by its proprietary Glyph™ Technology Platform, which leverages the lymphatic system to create new medicines building on clinically validated mechanisms. The financing will support the rapid advancement of Seaport’s clinical-stage pipeline of first and best-in-class medicines as well as further development of the Glyph platform, which has demonstrated clinical proof-of-concept. The company is built on a proven development strategy and is led by the team that created and advanced the groundbreaking drug candidate KarXT (xanomeline-trospium), which is now poised to be the first new class of medicine in over 50 years for patients living with schizophrenia. Daphne Zohar, the Chief Executive Officer of Seaport, is the founder and former CEO of PureTech Health where she also co-founded Karuna Therapeutics. Under Ms. Zohar’s leadership, PureTech’s R&D engine led to 28 new medicines, including two that received U.S. FDA clearance and a third (KarXT) that has been filed for FDA approval. Dr. Paul, Founder and Chair of the Seaport Board of Directors, is the former CEO and Chair of the Board of Directors of Karuna Therapeutics, which was recently acquired by Bristol Myers Squibb. Dr. Paul is also the former President of Research and Development at Eli Lilly, where he oversaw the development of CNS drugs such as Zyprexa® and Cymbalta® as well as xanomeline, where its anti-psychotic and pre-cognitive properties were initially demonstrated. "Major depression and anxiety disorders are among the most common, disabling and potentially fatal of all medical conditions. Current standard-of-care treatments provide inadequate relief for far too many patients. Seaport’s pipeline of investigational antidepressants and anxiolytics are well positioned to more effectively treat these disorders and to help millions of people and their families,” said Steven M. Paul M.D. “Given the historically low success rates within neuropsychiatric drug development, precisely solving the previous limitations of clinically validated mechanisms improves the probability of success and enables us to significantly accelerate development.” “We are dedicated to bringing first and best-in-class medicines to those that are suffering from depression, anxiety and other neuropsychiatric disorders,” said Daphne Zohar, Founder and CEO of Seaport Therapeutics. “I’m excited to deliver on this mission along with a stellar team of senior leaders and investors.” All of the programs in Seaport’s pipeline are based on the Glyph platform, which is designed to enable and enhance oral bioavailability, avoid first-pass metabolism and reduce hepatotoxicity and other side effects to advance active drugs that were previously held back by those limitations. Seaport’s most advanced therapeutic candidate is SPT-3001, which is an oral prodrug of allopregnanolone, an endogenous neurosteroid, in development for the treatment of anxious depression. Allopregnanolone has demonstrated therapeutic benefit in a range of neuropsychiatric conditions, but it is only approved as an intravenous infusion, which has limited the scope of its clinical use. Using the Glyph platform, SPT-300 retains the activity and potency of endogenous allopregnanolone in an oral form and has the potential to capture the breadth of the natural biological response. In a Phase 2a clinical trial, SPT-300 demonstrated proof-of-concept in a validated clinical model of anxiety in healthy volunteers. Seaport’s pipeline also includes SPT-3202, a novel prodrug of agomelatine being advanced for the treatment of Generalized Anxiety Disorder, which uses the Glyph platform to bypass first-pass metabolism by the liver and thus has the potential to lower its effective dose, reduce liver exposure and eliminate the need for liver function monitoring that has held back agomelatine. SPT-348, a prodrug of a non-hallucinogenic neuroplastogen in development for the treatment of mood and other neuropsychiatric disorders, leverages Glyph to create a potential first-in-class treatment with improved pharmacokinetics and tolerability compared to conventional psychedelics. Beyond these programs, Seaport has multiple discovery and preclinical programs underway. The additional members joining the Seaport Board of Directors are Robert Nelsen (Managing Partner and Co-founder of ARCH Venture Partners), James Healy, M.D., Ph.D. (Managing Partner of Sofinnova Investments), Eric Elenko, Ph.D. (Co-founder and President of PureTech and Co-inventor of KarXT), and Bharatt Chowrira Ph.D., (newly appointed Chief Executive Officer of PureTech). Courtney Wallace (Venture Partner at Third Rock Ventures) is joining as Board Observer. “I’m thrilled to be partnering again with this outstanding team, led by Daphne and Steve, to change the lives of people with neuropsychiatric disorders,” said Robert Nelsen, Co-founder and Managing Director of ARCH Venture Partners. “We were the lead investors in Karuna’s Series A and Series B financing rounds, and I’m excited to partner with these strong leaders again to deliver on Seaport’s proven strategy and robust pipeline and bring important new medicines to patients.” “Seaport has the potential to meaningfully change the lives of patients with neuropsychiatric disorders,” said James Healy, M.D., Ph.D., Managing Partner at Sofinnova Investments. “We’ve had the pleasure of knowing Steve and Daphne for a number of years, as one of the investors in Karuna, and we believe this team has the unique expertise to help solve the challenges of treating serious mental health conditions. I am eager to support Seaport as an investor and board member as the team continues to advance its clinical-stage pipeline of novel therapeutics.” About the Glyph™ Platform Glyph is Seaport's proprietary technology platform which uses the lymphatic system to enable and enhance the oral administration of drugs. With the Glyph platform, drugs are absorbed like dietary fats through the intestinal lymphatic system and transported into circulation. Seaport believes the Glyph technology has the potential to be widely applied to many therapeutic molecules that have high first-pass metabolism leading to low bioavailability and/or side effects, including hepatotoxicity. The Glyph platform has been refined at Seaport to efficiently generate multiple therapeutic candidates within the company’s pipeline. Seaport has exclusively licensed this technology from Monash University based on the pioneering research of the Porter research group, along with the co-inventors from PureTech Health and Seaport. The group and its collaborators have published research in Nature Metabolism, Frontiers in Pharmacology and the Journal of Controlled Release supporting the Glyph platform's capabilities. About Seaport Therapeutics Seaport Therapeutics is a clinical-stage biopharmaceutical company advancing the development of novel neuropsychiatric medicines in areas of high unmet patient needs. We have a proven strategy of advancing clinically validated mechanisms previously held back by limitations we overcome with our proprietary Glyph™ technology platform. All the therapeutic candidates in our pipeline of first and best-in-class medicines are based on the Glyph platform, which is uniquely designed to enable oral bioavailability, bypass first-pass metabolism and reduce hepatotoxicity and other side effects. We are led by an experienced team that was involved in inventing and advancing KarXT and other neuropsychiatric medicines and are guided by an extensive network of renowned scientists, clinicians and key opinion leaders across neurological specialties. For more information, please visit . Footnotes 1 SPT-300, formerly known as LYT-300 2 SPT-320, formerly known as LYT-320 View source version on businesswire.com: Contacts Seaport Therapeutics publicrelations@seaporttx.com Media Nichole Bobbyn +1 774 278 8273 nichole@tenbridgecommunications.com Source: Seaport Therapeutics View this news release online at:

临床2期高管变更临床结果

100 项与 Xanomeline 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D06330	Xanomeline	-	DB15357

研发状态

适应症	最高研发状态	国家/地区	公司
阿尔茨海默症	终止	美国更多	Eli Lilly & Co. 更多
精神分裂症	无进展	美国更多	Karuna Therapeutics, Inc. 更多
精神障碍	无进展	美国更多	The Fifth People's Hospital of Shenyang 更多

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT02831231 (Corporate Publications) 人工标引	临床1期	-	70	Xanomeline+trospium	鬱鹹構齋鬱積築繭糧憲(鹹衊衊製鬱糧鑰鑰鏇淵) = 願膚鹽鹹醖築獵觸繭鑰廠襯選顧艱築獵網獵繭 (襯積積衊築壓壓蓋衊範 ) 更多	积极	2019-08-14
				Placebo+Xanomeline	鬱鹹構齋鬱積築繭糧憲(鹹衊衊製鬱糧鑰鑰鏇淵) = 繭齋窪築獵壓衊憲憲獵廠襯選顧艱築獵網獵繭 (襯積積衊築壓壓蓋衊範 ) 更多